BAJAJ BROKING
Torrent Pharmaceuticals will acquire three anti-diabetes brands from Boehringer Ingelheim by March 2025. The ₹19,912 crore diabetes medication market grows at 7.7% CAGR, supporting Torrent Pharmaceuticals share price optimism.
Torrent Pharmaceuticals Ltd has entered into an agreement to acquire three anti-diabetes brands—Cospiaq, Cospiaq Met, and Xilingio—from Boehringer Ingelheim International GmbH. These brands, which feature empagliflozin as a key ingredient, are used in glycemic control for type 2 diabetes mellitus patients. Torrent has been co-marketing these brands since 2022. The acquisition, expected to close by March 2025, will further strengthen the company's diabetes care portfolio in India.
Also read: Bharat Forge Launches QIP, Sets Floor Price At ₹1,323.54 Per Share
Brands Acquired: Cospiaq, Cospiaq Met, and Xilingio.
Completion Timeline: March 2025.
Key Ingredient: Empagliflozin, an SGLT-2 inhibitor.
Indian Diabetes Market: Valued at ₹19,912 crore, growing at 7.7% CAGR.
Torrent Pharmaceuticals Share Price Impact: Positive momentum expected.
Also read: Bondada Engineering Secures ₹108.9 Crore Order From BREDA
India has the second-largest population of diabetes patients, with an estimated 74.2 million adults as of 2021, projected to rise to 125 million by 2045. The market for SGLT-2 inhibitors, such as empagliflozin, is valued at ₹3,235 crore and is expanding rapidly at a CAGR of 25%, outpacing the overall diabetes market growth.
Details | Figures |
Diabetes Patient Base (2021) | 74.2 million |
Estimated Patients (2045) | 125 million |
Indian Diabetes Medication Market | ₹19,912 crore |
SGLT-2 Inhibitors Market | ₹3,235 crore |
SGLT-2 Inhibitors Growth Rate (CAGR) | 25% |
Torrent’s acquisition is a strategic move to deepen its presence in the ₹19,912 crore Indian diabetes medication market. With the demand for effective diabetes management solutions growing, the acquisition of these brands enhances Torrent’s ability to cater to this expanding segment while bolstering its position in the oral anti-diabetic space.
This development is expected to generate positive investor sentiment, supporting Torrent Pharmaceuticals share price. The deal highlights the company’s focus on growth within high-potential therapeutic areas, particularly in the rapidly expanding diabetes segment.
Torrent Pharmaceuticals’ acquisition of anti-diabetes brands from Boehringer Ingelheim reinforces its leadership in the diabetes care market. With robust market growth and increasing patient needs, the move is expected to strengthen the company's portfolio and favourably influence Torrent Pharmaceuticals share price.
Also read: Vodafone Idea Board to Meet on Dec 9 to Discuss ₹2,000 Crore Fundraising
Disclaimer: Investments in the securities market are subject to market risk, read all related documents carefully before investing.
This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.
For All Disclaimers Click Here: https://bit.ly/3Tcsfuc
Share this article:
Disclaimer :
The information on this website is provided on "AS IS" basis. Bajaj Broking (BFSL) does not warrant the accuracy of the information given herein, either expressly or impliedly, for any particular purpose and expressly disclaims any warranties of merchantability or suitability for any particular purpose. While BFSL strives to ensure accuracy, it does not guarantee the completeness, reliability, or timeliness of the information. Users are advised to independently verify details and stay updated with any changes.
The information provided on this website is for general informational purposes only and is subject to change without prior notice. BFSL shall not be responsible for any consequences arising from reliance on the information provided herein and shall not be held responsible for all or any actions that may subsequently result in any loss, damage and or liability. Interest rates, fees, and charges etc., are revised from time to time, for the latest details please refer to our Pricing page.
Neither the information, nor any opinion contained in this website constitutes a solicitation or offer by BFSL or its affiliates to buy or sell any securities, futures, options or other financial instruments or provide any investment advice or service.
BFSL is acting as distributor for non-broking products/ services such as IPO, Mutual Fund, Insurance, PMS, and NPS. These are not Exchange Traded Products. For more details on risk factors, terms and conditions please read the sales brochure carefully before investing.
Investments in the securities market are subject to market risk, read all related documents carefully before investing. This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.
For more disclaimer, check here : https://www.bajajbroking.in/disclaimer
Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading